Cardiometabolic risk factors in treatment-seeking youth versus population youth with obesity

C. K. Fox¹, A. M. Kaizer², J. R. Ryder¹, K. D. Rudser², A. S. Kelly¹, S. Kumar³, A. C. Gross¹ and on behalf of POWER Work Group

¹Department of Pediatrics, University of Minnesota, Minneapolis, USA; ²Department of Biostatistics, University of Minnesota, Minneapolis, USA; ³Mayo Clinic, Rochester, USA

Received 8 November 2017; revised 20 February 2018; accepted 22 February 2018

Address for correspondence: C Fox, M.D., M.P.H., University of Minnesota, Department of Pediatrics, 2450 Riverside Avenue, 6th Floor, East Building, Minneapolis, MN 55454, USA. E-mail: lusc0001@umn.edu

Summary

Background

Although obesity affects approximately one in five youths, only a fraction is treated in pediatric weight management clinics. Characteristics distinguishing youth with obesity who seek weight management treatment from those who do not are largely unknown. Yet identification of specific health characteristics which differentiate treatment-seeking from non-treatment-seeking youth with obesity may shed light on underlying motivations for pursuing treatment.

Objectives

Compare the cardiometabolic profiles of an obesity treatment-seeking sample of youth to a population-based sample of youth with obesity, while controlling for body mass index (BMI).

Methods

This cross-sectional study included participants, ages 12–17 years, with obesity from the Pediatric Obesity and Weight Evaluation Registry (POWER) and National Health and Nutrition Examination Survey, representing the treatment-seeking and population samples, respectively. Mean differences were calculated for systolic and diastolic blood pressure percentiles, total cholesterol, low-density and high-density lipoprotein-cholesterol, triglycerides, fasting glucose, glycated hemoglobin and alanine aminotransferase, while adjusting for age, sex, race/ethnicity, insurance status, and multiple of the 95th BMI percentile.

Results

The POWER and National Health and Nutrition Examination Survey cohorts included 1,823 and 617 participants, respectively. The POWER cohort had higher systolic blood pressure percentile (mean difference 17.4, 95% confidence interval [14.6, 20.1], p < 0.001), diastolic blood pressure percentile (21.8 [19, 24.5], p < 0.001), triglycerides (42.3 [28, 56.5], p < 0.001) and alanine aminotransferase (7.5 [5.1, 9.8], p < 0.001) and lower fasting glucose (-6.9 [-8.2, -5.6], p < 0.001) and high-density lipoprotein-cholesterol (-2.3 [-3.8, -0.9], p < 0.002). There were no differences in total cholesterol or low-density lipoprotein-cholesterol or clinical differences in glycated hemoglobin.

Conclusion

For a given BMI, obesity treatment-seeking youth are more adversely affected by cardiometabolic risk factors than the general population of youth with obesity. This suggests that treatment-seeking youth may represent a distinct group that is at particularly high risk for the development of future cardiometabolic disease.

Keywords: Cardiometabolic risk factor, population, treatment seeking.
Introduction

Youth with obesity who fail to improve their body mass index (BMI) via primary care clinic interventions should be referred to comprehensive multidisciplinary weight management programs (1). These multidisciplinary programs provide intensive lifestyle modification therapy and, when indicated, more aggressive treatments such as pharmacotherapy and bariatric surgery to improve weight status and obesity-related comorbidities (1,2). Although approximately one in five youths in the USA is afflicted with obesity (3), only a small fraction are treated in such multidisciplinary programs. Identification of specific health characteristics which differentiate youth with obesity who seek weight management treatment programs versus those who do not may shed light on underlying motivations for patients to seek such treatment. Furthermore, identification of the differential health characteristics of treatment-seeking youth may have implications for access to such care and should inform the types of interventions provided by these multidisciplinary programs.

To date, only small studies have examined differences between population samples and treatment-seeking samples of youth with obesity, and most of these have focused on rates of mental illness. Although most of these studies suggest that treatment-seeking youth with obesity have higher rates of mental health disorders compared with population samples of youth with obesity (4–6), it is not known if these differences extend to cardiometabolic risk factors and other obesity-related comorbidities. Accordingly, the aim of this study was to compare the cardiometabolic risk factor profiles between two large, contemporary cohorts of youth with obesity: a treatment-seeking sample derived from the Pediatric Obesity Weight Evaluation Registry (POWER) (7) and a population sample derived from the National Health and Nutrition Examination Survey (NHANES). Owing to the fact that comorbidities such as hypertension, impaired glucose tolerance and dyslipidemia are largely driven by degree of adiposity, it was hypothesized that treatment-seeking and population samples of youth with obesity would have similarly high rates of cardiometabolic derangements when accounting for BMI.

Methods

Sample

This cross-sectional study compared two large contemporary cohorts of adolescents with obesity: an obesity treatment-seeking sample and a population-based sample. The treatment-seeking cohort was obtained from the POWER. POWER, established in 2013, is an ongoing national registry of patients ≤18 years of age with obesity (age-specific and sex-specific BMI ≥95th percentile) who are seeking care in 1 of 27 multicomponent pediatric weight management clinics/programs from 20 states in the USA (ClinicalTrials.gov NCT02121132). The purpose of POWER is to identify the characteristics of patients and clinics/programs in order to identify variables that predict favorable outcomes. Program inclusion criteria include those that provide multicomponent pediatric weight management treatment for youth with obesity and that agree to collect the required data elements including patient height, weight, age, race and ethnicity. Each program was responsible for obtaining IRB approval. More information on the establishment of POWER is available elsewhere (7). POWER data for this study were collected from May 2014 through April 2016. All POWER sites endorsed this study. The population-based cohort of youth with obesity was obtained from NHANES 2009–2010, 2011–2012 and 2013–2014 data cycles to utilize available data that best matched the duration when POWER data was collected while increasing the sample size. NHANES is a continuous annual survey of the US population’s health that was started in 1999 and releases data to the public in 2-year intervals (8). NHANES includes subject interviews, physical examinations and fasting laboratory evaluations.

From both samples, POWER and NHANES, participants were included if they were between 12 and 17 years of age, had obesity (age-specific and sex-specific BMI ≥95th percentile), and had at least one of the following outcomes measured: systolic blood pressure, diastolic blood pressure, total cholesterol (TC), LDL-cholesterol (LDL-c), HDL-cholesterol (HDL-c), triglycerides (TG), non-HDL-cholesterol (non-HDL-c), fasting glucose (FG), fasting insulin, and hemoglobin A1c (HbA1c). Participants missing all outcomes were excluded (43 from POWER and 11 from NHANES), as were those with glucose and/or HbA1c values consistent with diabetes.

Measures and definitions

Self-reported age, race and ethnicity were collected from both POWER and NHANES, and for this study race and ethnicity were combined into one category. Height, weight and blood pressure were measured at the baseline visits to the weight management programs/clinics for the POWER cohort and by trained personnel in the NHANES cohort. Fasting lipid panel, FG, fasting insulin, HbA1c and
ALT were collected at baseline or within 6 months prior to the baseline visits for the POWER sample and according to standard protocols for the NHANES sample. See Table 1 for definitions of cut-points for classes I, II and III obesity (9), elevated blood pressure (10), dyslipidemia (11), prediabetes, homeostasis model assessment-insulin resistance (HOMA-IR), and abnormal ALT (12).

Statistical analysis

To account for the complex, multilevel sampling structure of NHANES, sampling weights were provided for each individual with the data (8). Given the structure of POWER, there are no provided sampling weights, so equal sample weight was assumed for each subject. Sampling weights were normalized to sum to 1 within each study, and then normalized in the combined POWER/NHANES dataset by the proportion of data coming from each study. Descriptive characteristics of the POWER and NHANES cohorts were calculated with weighted mean (weighted SD) or weighted % to account for the weighted structure of the data. All analyses were conducted in R v3.3.1. (13). The survey package in R was used to take into account the weighted structure of the data for analyses for all linear and logistic regressions.

Table 1: Definitions of normal and abnormal measures of cardiometabolic variables

| Cardiometabolic variable | Cutoffs |
|--------------------------|---------|
| Obesity                  | Class I BMI ≥100% of 95th percentile  |
|                          | Class II BMI ≥120% of 95th percentile |
|                          | Class III BMI ≥140% of 95th percentile |
| Blood pressure           | Normal if SBP and DBP < 90th percentile |
|                          | Pre-HTN if SBP or DBP ≥90th and < 95th percentile |
|                          | HTN if SBP or DBP ≥95th percentile |
| Glucose                  | Non-diabetic if HbA1c < 5.7% and fasting glucose < 100 mg/dL |
|                          | Pre-diabetic if HbA1c 5.7–6.4% or fasting glucose 100–125 mg/dL |
|                          | Diabetic if HbA1c ≥6.5% or fasting glucose ≥126 mg/dL |
| LDL-c                    | Normal if LDL-c < 110 mg/dL |
|                          | Borderline High if LDL-c 110–130 mg/dL |
|                          | High if LDL-c ≥ 130 mg/dL |
| Triglycerides            | Normal if triglycerides <90 mg/dL |
|                          | Borderline high if triglycerides 90–129 |
|                          | High if triglycerides ≥130 mg/dL |
| HDL-c                    | Normal if HDL-c ≥ 45 mg/dL |
|                          | Borderline Low if HDL-c 40–45 mg/dL |
|                          | Low if HDL-c ≤ 40 mg/dL |
| ALT                      | Normal ALT <25 U/L (males); <22 U/L (female patients) |
|                          | Moderately elevated ALT 25–40 (male patients); 22–40 (female patients) |
|                          | Severely elevated if ALT ≥40 (male and female patients) |

BMI, body mass index; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL-c, HDL-cholesterol; LDL-c, LDL-cholesterol; SBP, systolic blood pressure.

© 2018 The Authors
Obesity Science & Practice published by John Wiley & Sons Ltd, World Obesity and The Obesity Society. Obesity Science & Practice

Results

The POWER cohort included 1,823 subjects and the NHANES cohort included 617. Demographics, BMI classifications and cardiometabolic variables are presented in Table 2. There was an equal distribution of sex, although the POWER sample had a lower proportion of white and privately insured participants. The POWER sample had more participants with classes II and III obesity, pre-hypertension, hypertension, prediabetes, high LDL-c, high TG, low HDL-c and elevated ALT.

When comparing the mean differences of discrete values between POWER and NHANES (Table 3) while adjusting for age, sex, race/ethnicity, insurance status and multiple of the 95th BMI percentile, the POWER sample overall and for each of the three obesity classes had clinically and statistically higher systolic blood pressure, diastolic blood pressure and ALT and lower FG. Also, the POWER sample overall had higher TG and lower HDL-c. The POWER and NHANES samples overall and in each of the obesity classes showed no consistent differences in TC, LDL-c, fasting insulin and HOMA-IR, or clinical differences in HbA1c.

The odds of meeting criteria for hypertension was 8.72 times higher (p < 0.001) for those in POWER compared with NHANES. The odds of having high triglycerides, low HDL-c or high ALT were each approximately twice as high for the POWER participants compared with the NHANES participants. The odds of having high LDL-c or prediabetes was not statistically different between groups (Table 4).

Discussion

In comparing the cardiometabolic profiles between a treatment-seeking sample of youth with obesity and a population sample of youth with obesity, only TC, LDL-c, HbA1c, insulin and HOMA-IR were similar between these two samples, even when adjusting for BMI and demographics. The treatment-seeking youth with obesity had higher TG, lower HDL-c, higher blood pressure and higher ALT compared with the population sample of youth with obesity. Paradoxically, treatment-seeking youth had lower FG. These differences remained consistent, for the most part, when youth were separated into different categories of degree of obesity.
In the general pediatric population and even in the context of obesity, high LDL-c is rare and is usually related to familial hypercholesterolemia; thus, the lack of difference in LDL-c between the treatment-seeking sample and the population sample of youth with obesity is not surprising. However, because the aetiology of high TG and low HDL-c is often related to adiposity, comparable levels of TG and HDL-c between the treatment-seeking and population cohorts were expected when adjusting for BMI. The unexpectedly identified differences may be related to a referral bias in that the American Academy of Pediatrics recommends screening for dyslipidemia in children with obesity (1) and abnormal results may have served as a prompt for referral to a pediatric weight management program.

The prevalence of hypertension in the general population of youth is approximately 2–4% (14). Yet, in this study of youth with obesity, the population cohort prevalence was only 1.8% and substantially more in the treatment-seeking sample at 20%. While obesity is associated with elevated blood pressure, the Bogalusa Heart Study, a large longitudinal study of cardiovascular disease risk factors in youth, found that the correlation between BMI and blood pressure was only 0.3 (15). Thus, other unmeasured variables are likely contributing to the high blood pressure in the treatment-seeking group or perhaps these patients represent a different phenotype of children with obesity who have particularly adverse metabolic profiles including high blood pressure (16). Additionally, there may be more “white coat hypertension” in the treatment-seeking group compared with the population-based sample or there may be more technical difficulties related to measuring blood pressure in the clinical setting (such as cuff-size) which may not be present in the more standardized, research setting. Finally, the higher prevalence of hypertension in the treatment-seeking cohort may also be related to referral bias as, similar to dyslipidemia screening, the American Academy of Pediatrics recommends universal screening for elevated blood pressure (17).

Regarding the diabetes risk lab tests, no discernible or clinically meaningful differences in HbA1c, insulin, HOMA-IR or diagnosis of prediabetes (impaired FG or borderline HbA1c) between groups were identified, as hypothesized. In contrast to these findings, lower FG levels in the treatment-seeking sample of children were observed. The explanation for this finding is unclear and cannot be determined from this study. Speculatively, this finding could be related to differences in Tanner stage between cohorts, which is known to influence insulin and glucose metabolism (18). Moreover, this finding could be spurious as large population-based studies are conflicted as to whether using FG or HbA1c is the most appropriate metric for determining prediabetes/diabetes risk and prevalence (19). Finally, the differences in FG levels may be related to differences in the laboratory analysis methods between the two cohorts. While the NHANES laboratory methods are standardized, the POWER methods are not.

Table 2  Summary of demographics and cardiometabolic risk factors for POWER and NHANES cohorts overall

| Co-variates                        | POWER | NHANES |
|------------------------------------|-------|--------|
| N                                  | 1,823 | 617    |
| Female                             | 55.5% | 50.2%  |
| 15–17 Years old                    | 41.1% | 49.2%  |
| Race/Ethnicity                     |       |        |
| Black/African American             | 20.6% | 16.4%  |
| Hispanic/Latino                    | 26.4% | 24.4%  |
| Other/Multiracial                  | 10.9% | 7.4%   |
| White                              | 42.2% | 51.8%  |
| Insurance Type                     |       |        |
| None                               | 0.8%  | 0.1%   |
| Private only                       | 31.2% | 47.3%  |
| Public only                        | 57.3% | 41.8%  |
| Private+Public                     | 0.0%  | 2.9%   |
| Unknown insurance                  | 10.5% | 0.0%   |
| Missing                            | 0.2%  | 7.9%   |
| Any insurance coverage             | 88.5% | 92.1%  |
| Missing                            | 10.7% | 0.2%   |
| BMI classification                 |       |        |
| Class 1 obesity                    | 27.4% | 62.9%  |
| Class 2 obesity                    | 35.7% | 24.6%  |
| Class 3 obesity                    | 36.9% | 12.5%  |
| Cardiometabolic variables         |       |        |
| Non-hypertensive                   | 66.6% | 91.5%  |
| Pre-hypertension                   | 11.5% | 5.6%   |
| Hypertension                       | 20.0% | 1.8%   |
| Missing                            | 1.9%  | 1.1%   |
| Prediabetes                        | 13.2% | 10.3%  |
| Missing                            | 61.7% | 70.3%  |
| Normal LDL                         | 32.0% | 30.6%  |
| Borderline high LDL                | 5.9%  | 7.1%   |
| High LDL                           | 4.4%  | 2.0%   |
| Missing                            | 57.8% | 60.3%  |
| Normal triglycerides               | 14.8% | 23.6%  |
| Borderline high triglycerides      | 12.0% | 7.8%   |
| High triglycerides                 | 16.3% | 8.4%   |
| Missing                            | 56.9% | 60.2%  |
| Normal HDL-c                       | 14.4% | 17.1%  |
| Borderline low HDL-c               | 9.9%  | 12.7%  |
| Low HDL-c                          | 18.5% | 12.4%  |
| Missing                            | 57.2% | 57.8%  |
| Normal ALT                         | 24.7% | 58.8%  |
| Moderate ALT elevation             | 24.1% | 21.5%  |
| Severe ALT elevation               | 14.0% | 9.5%   |
| Missing                            | 37.2% | 10.2%  |

Values presented are weighted %. HDL-c, HDL-cholesterol; LDL, low-density lipoprotein.
Table 3  Mean difference between POWER and NHANES adjusted for sex, age, race/ethnicity (African American, Asian/Other, Latino/Hispanic and White), insurance status (Private or Private/Public, Public or None, Missing or Unknown) and multiple of the 95th BMI percentile for all subjects and each obesity class

| Outcome                   | POWER mean (SD) | NHANES mean (SD) | Adjusted mean difference (POWER-NHANES) (95% CI) | P-value |
|---------------------------|-----------------|------------------|------------------------------------------------|---------|
| All subjects              |                 |                  |                                                |         |
| Systolic BP (mm Hg)       | 118.9 (12.1)    | 111.1 (10.2)     | 6.5 (5.5, 7.6)                                 | <0.001  |
| Systolic BP percentile    | 67.8 (26.5)     | 46.9 (26.4)      | 17.3 (14.5, 20.1)                              | <0.001  |
| Diastolic BP (mm Hg)      | 69.1 (9.9)      | 57.7 (13.9)      | 10.1 (8.8, 11.4)                               | <0.001  |
| Diastolic BP percentile   | 60 (25.1)       | 34.6 (26.8)      | 21.9 (19.1, 24.7)                              | <0.001  |
| HbA1c (%)                 | 5.4 (0.4)       | 5.3 (0.3)        | 0.1 (0.0, 0.1)                                 | 0.038   |
| Fasting glucose (mg/dL)   | 89.3 (8.8)      | 95.7 (7.1)       | −6.9 (−8.2, −5.6)                              | <0.001  |
| Fasting insulin (uU/mL)   | 26 (23)         | 24.9 (13.4)      | −2.3 (−5.1, 0.8)                               | 0.117   |
| HOMA-IR                   | 5.8 (5.2)       | 5.9 (3.4)        | −0.9 (−1.6, −0.2)                              | 0.014   |
| Total cholesterol (mg/dL) | 159.4 (33.6)    | 155.6 (23.3)     | 3.6 (−1.1, 8.2)                                | 0.131   |
| LDL-c (mg/dL)             | 92.5 (29.8)     | 90.9 (24.7)      | 0.8 (−3.3, 4.9)                                | 0.707   |
| Triglycerides (mg/dL)     | 131.9 (81.3)    | 95.6 (59.2)      | 33.6 (22.9, 44.3)                              | <0.001  |
| HDL-c (mg/dL)             | 42 (10.5)       | 45.7 (9.6)       | −2.4 (−3.9, −0.9)                              | 0.002   |
| Non-HDL-c (mg/dL)         | 117.3 (36.1)    | 109.9 (28)       | 5.9 (1.3, 10.4)                                | 0.012   |
| ALT (U/L)                 | 33.4 (29)       | 24.2 (19.1)      | 7.8 (5.5, 10.1)                                | <0.001  |
| Class 1 obesity           |                 |                  |                                                |         |
| Systolic BP (mm Hg)       | 115.7 (11.8)    | 109.7 (9.8)      | 6.0 (5.2, 8.3)                                 | <0.001  |
| Diastolic BP (mm Hg)      | 62.4 (27.5)     | 43.5 (26.3)      | 18.9 (14.8, 23)                                | <0.001  |
| Diastolic BP percentile   | 66.9 (9.6)      | 56.9 (13.8)      | 10.4 (8.4, 12.3)                               | <0.001  |
| HbA1c (%)                 | 54.9 (25)       | 32.6 (26.1)      | 21.9 (17.9, 26)                                | <0.001  |
| Fasting glucose (mg/dL)   | 88.6 (8.5)      | 94.6 (7)         | −6.2 (−8.1, −4.3)                              | <0.001  |
| Fasting insulin (uU/mL)   | 20.9 (22.4)     | 19.7 (8.3)       | 0.2 (−4.2, 4.5)                                | 0.939   |
| HOMA-IR                   | 4.7 (5.2)       | 4.6 (2.1)        | −0.2 (−1.2, 0.8)                               | 0.710   |
| Total cholesterol (mg/dL) | 158.7 (34.8)    | 153.9 (27.5)     | 4.4 (−2.2, 11)                                 | 0.190   |
| LDL-c (mg/dL)             | 91.1 (29.9)     | 87.6 (23.9)      | 3.5 (−2.5, 8.6)                                | 0.255   |
| Triglycerides (mg/dL)     | 133.5 (85.6)    | 97.3 (62.4)      | 32.3 (15.7, 48.8)                              | <0.001  |
| HDL-c (mg/dL)             | 43 (10.2)       | 46.5 (9.6)       | −2.8 (−4.9, −0.7)                              | 0.010   |
| Non-HDL-c (mg/dL)         | 115.5 (35.9)    | 107.4 (27.8)     | 6.9 (3.3, 13.6)                                | 0.041   |
| ALT (U/L)                 | 22.8 (20.1)     | 22.8 (20.8)      | 5.7 (2.1, 9.3)                                 | 0.002   |
| Class 2 obesity           |                 |                  |                                                |         |
| Systolic BP (mm Hg)       | 117.5 (10.5)    | 111.4 (10.5)     | 6.1 (4.8, 8.5)                                 | <0.001  |
| Diastolic BP (mm Hg)      | 65.5 (25.8)     | 47.4 (25.2)      | 17.1 (13, 22.6)                                | <0.001  |
| Diastolic BP percentile   | 68.2 (9.3)      | 56.7 (13.4)      | 10.7 (8.4, 13.1)                               | <0.001  |
| HbA1c (%)                 | 58.4 (24.7)     | 33.9 (26.4)      | 24.5 (19.5, 29.5)                              | <0.001  |
| Fasting glucose (mg/dL)   | 89.3 (8.1)      | 98.2 (7.6)       | −8.2 (−10.7, −5.8)                             | <0.001  |
| Fasting insulin (uU/mL)   | 23.2 (15.9)     | 31.7 (15.8)      | −7.5 (−12.5, −2.5)                             | 0.004   |
| HOMA-IR                   | 5.1 (3.7)       | 7.8 (4.3)        | −2.3 (−3.7, −1)                                | <0.001  |
| Total cholesterol (mg/dL) | 163.7 (39.1)    | 159.1 (30.9)     | 3.8 (−4.9, 12.5)                               | 0.396   |
| LDL-c (mg/dL)             | 94.8 (32)       | 96.5 (26.7)      | −1.9 (−9.2, 5.4)                               | 0.607   |
| Triglycerides (mg/dL)     | 133 (86.8)      | 88.7 (42.1)      | 42 (27.8, 56.3)                                | <0.001  |
| HDL-c (mg/dL)             | 42.6 (10)       | 45.2 (10.2)      | −2.8 (−5.6, 0)                                 | 0.053   |
| Non-HDL-c (mg/dL)         | 120.7 (40)      | 113.9 (29.9)     | 6.2 (−2.2, 14.7)                               | 0.149   |
| ALT (U/L)                 | 34 (29.3)       | 26.1 (16)        | 8.4 (4.1, 11.7)                                | <0.001  |
| Class 3 obesity           |                 |                  |                                                |         |
| Systolic BP (mm Hg)       | 122.6 (12.7)    | 116.1 (10)       | 5.8 (3.6, 8.1)                                 | <0.001  |
| Diastolic BP (mm Hg)      | 74.1 (25.2)     | 59.4 (25.4)      | 11.3 (5.2, 17.5)                               | <0.001  |
| Diastolic BP percentile   | 71.5 (10.3)     | 61.3 (14.8)      | 9.2 (5.8, 12.6)                                | <0.001  |
| HbA1c (%)                 | 65.3 (24.4)     | 44.3 (28.2)      | 18 (11.2, 24.8)                                | <0.001  |
| Fasting glucose (mg/dL)   | 90 (9.6)        | 96.5 (5.6)       | −7.5 (−10, −4.9)                                | <0.001  |

Continues
Elevated ALT, which has its limitations in that it underestimates liver pathology in youth (12, 20), is nonetheless a clinically relevant marker of nonalcoholic fatty liver disease (NAFLD). Youth with obesity and severe obesity often present with NAFLD (38–65%) at higher prevalence rates than in the general population (13%) as defined by

Table 3. Continued

| Outcome                  | POWER mean (SD) | NHANES mean (SD) | Adjusted mean difference (POWER-NHANES) (95% CI) | P-value |
|--------------------------|-----------------|------------------|--------------------------------------------------|---------|
| Fasting insulin (uU/mL)  | 33.6 (27.7)     | 32.6 (15.3)      | -0.4 (-9.3, 8.4)                                 | 0.923   |
| HOMA-IR                  | 7.4 (6.1)       | 7.7 (3.5)        | -0.6 (-2.5, 1.4)                                 | 0.576   |
| Total cholesterol (mg/dL)| 155.8 (31.9)    | 156.8 (26)       | -0.9 (-11.1, 9.4)                                | 0.871   |
| LDL-c (mg/dL)            | 91.4 (27.1)     | 94.1 (21.7)      | -2.6 (-11, 5.8)                                  | 0.541   |
| Triglycerides (mg/dL)    | 129.2 (68.6)    | 101.5 (70.1)     | 21.6 (-3.8, 46.9)                                | 0.097   |
| HDL-c (mg/dL)            | 40.5 (11.1)     | 42.7 (7.7)       | -1 (-4.3, 2.3)                                   | 0.556   |
| Non-HDL-c (mg/dL)        | 115.5 (31.4)    | 114.1 (24.2)     | 0.4 (-8.7, 9.5)                                  | 0.937   |
| ALT (U/L)                | 36.5 (33.6)     | 27 (16.1)        | 9 (4.4, 13.6)                                    | <0.001  |

BMI, body mass index; BP, blood pressure; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment-insulin resistance; HDL-c, HDL-cholesterol; LDL-c, LDL-cholesterol; NHANES, National Health and Nutrition Examination Survey; POWER, Pediatric Obesity and Weight Evaluation Registry.

Table 4 Odds ratios between NHANES and POWER adjusted for sex, race/ethnicity (African American, Asian/Other, Latino/Hispanic and White), insurance status (Private or Private+Public, Public or None, Missing or Unknown) and multiple of the 95th BMI percentile for all subjects and each obesity class

| Outcome                  | POWER (%) | NHANES (%) | Adjusted odds ratio (95% CI) | P-value |
|--------------------------|-----------|------------|------------------------------|---------|
| All subjects             |           |            |                              |         |
| Hypertension criteria met| 20.4      | 2.2        | 8.60 (4.66, 15.86)           | <0.001  |
| Prediabetes              | 34.4      | 40.0       | 0.78 (0.53, 1.14)            | 0.202   |
| High LDL                 | 10.4      | 5.5        | 1.71 (0.90, 3.23)            | 0.101   |
| High triglycerides       | 38.0      | 20.3       | 2.17 (1.44, 3.26)            | <0.001  |
| Low HDL                  | 43.3      | 25.5       | 1.76 (1.23, 2.52)            | 0.002   |
| High ALT                 | 22.3      | 9.6        | 2.56 (1.76, 3.72)            | <0.001  |
| Class 1 obesity          |           |            |                              |         |
| Hypertension criteria met| 13.8      | 1.4        | 12.16 (4.31, 34.31)          | <0.001  |
| Prediabetes              | 27.7      | 30.3       | 0.81 (0.45, 1.47)            | 0.494   |
| High LDL                 | 10.5      | 4.5        | 2.21 (0.82, 5.97)            | 0.117   |
| High triglycerides       | 38.2      | 22.2       | 2.09 (1.20, 3.62)            | 0.009   |
| Low HDL                  | 38.6      | 22.4       | 1.94 (1.17, 3.24)            | 0.011   |
| High ALT                 | 15.7      | 7.5        | 2.06 (1.13, 3.74)            | 0.018   |
| Class 2 obesity          |           |            |                              |         |
| Hypertension criteria met| 16.0      | 2.1        | 9.99 (2.95, 33.83)           | <0.001  |
| Prediabetes              | 32.4      | 49.6       | 0.75 (0.37, 1.51)            | 0.415   |
| High LDL                 | 10.8      | 9.7        | 0.84 (0.32, 2.25)            | 0.734   |
| High triglycerides       | 34.9      | 14.1       | 3.06 (1.45, 6.47)            | 0.004   |
| Low HDL                  | 40.3      | 26.0       | 1.86 (0.99, 3.48)            | 0.055   |
| High ALT                 | 21.7      | 12.6       | 2.38 (1.31, 4.31)            | 0.005   |
| Class 3 obesity          |           |            |                              |         |
| Hypertension criteria met| 29.4      | 5.8        | 5.02 (1.90, 13.31)           | 0.001   |
| Prediabetes              | 41.8      | 56.2       | 0.56 (0.25, 1.23)            | 0.150   |
| High LDL                 | 9.8       | 2.3        | 4.09 (0.73, 23.03)           | 0.111   |
| High triglycerides       | 40.9      | 23.6       | 1.76 (0.71, 4.39)            | 0.227   |
| Low HDL                  | 50.6      | 38.0       | 1.42 (0.62, 3.22)            | 0.406   |
| High ALT                 | 27.9      | 13.0       | 2.72 (1.25, 5.93)            | 0.012   |

CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NHANES, National Health and Nutrition Examination Survey; POWER, Pediatric Obesity and Weight Evaluation Registry.
liver biopsy (21,22). Thus, while treatment-seeking youth had consistently higher ALT than the population-based sample, both samples likely have much higher prevalence rates of NAFLD than was suggested by their ALT.

Although this treatment-seeking cohort of youth with obesity had an overall worse cardiometabolic profile compared with the population-based sample of youth with obesity, the profiles of these treatment seekers are similar to other treatment-seeking cohorts from around the world. For example, a large survey of 26,008 children (mean age 12.6 years, 56% girls, mean BMI 29.4 kg/m²) with overweight (BMI > 90th percentile) or obesity (>97th percentile) who were treated in any of 98 weight management treatment centers from Germany, Austria and Switzerland examined the cardiometabolic status in these patients (23). Among the subgroup of patients with BMI > 99.5 percentile, the hypertension prevalence was nearly 45%, low HDL-c prevalence was 15% and high triglyceride prevalence was 17%.

The hypothesis for this study was that treatment-seeking youth with obesity and youth with obesity from the general population would have similarly poor cardiometabolic profiles when adjusting for BMI. This finding would have served as a “call to action” for more availability of weight management programs given the enormous number of youth with obesity who are not receiving obesity treatment. However, overall, the results were not consistent with this hypothesis. The reasons for the presence of differences in cardiometabolic profiles between treatment-seeking and population obesity are unclear but could be related to any number of unmeasured confounding variables. One of these variables, which may be especially relevant, is mental illness. Rates of mental illness are known to be higher among treatment-seeking youth with obesity compared with the general population of youth with obesity (4–6), and mental illness also has adverse effects on cardiometabolic health (24). Future studies should include measurements of mental illness as a potential moderator of the association between treatment-seeking status and poor cardiometabolic health.

Strengths of this study include the large sample size, nationally representative nature of both cohorts and generalizability of findings due to the racial/ethnic and gender distributions of the cohorts. Limitations of this study include methods of data collection were not uniform across the pediatric weight management clinics/programs used in the treatment-seeking sample and the amount of missing data. Also, confounding variables such as diet, physical activity, pubertal status, emotional stress/mental illness and direct measures of adiposity (particularly visceral adiposity) were not available for measurement. All of these factors, each to a variable degree, may be associated with cardiovascular disease risk factors and with obesity status. As stated earlier, referral bias may also account for some of the differences in cardiometabolic profiles between the treatment-seeking and population cohorts of youth with obesity. Specifically, it may be that those with comorbidities are more likely to be seen in weight management clinics. This bias would be exacerbated if weight management clinics require the presence of comorbidities as a prerequisite for referral. However, a survey of the programs included in POWER identified that 56% of the programs required potential patients to have a BMI > 85th percentile before enrolling and 36% of the programs required potential patients to have a BMI >95th percentile. Only 8% required the additional presence of a comorbid condition (7). Indeed, the American Academy of Pediatrics recommends that patients with obesity should be referred to multidisciplinary weight management programs when there is no weight loss achieved with less structured weight management interventions. The comorbidity status alone is not an indication for referral (1). Finally, the sample sizes of youth with classes II and III obesity in the treatment-seeking cohort were much larger than the population cohort which may have affected the outcomes.

Conclusion

In general, the prevalence of cardiometabolic risk factors increases with the degree of obesity in children and adolescents (25). However, this study demonstrated that for a given BMI, obesity treatment-seeking youth are more adversely affected by these risk factors than the general population of youth with obesity. This suggests that youth who are receiving care in multicomponent pediatric weight management clinics/programs may represent a distinct group that is at particularly high risk for the development of future cardiometabolic disease. Identification of factors contributing to the more adverse cardiometabolic profiles may provide insight into effective treatments.

Conflict of interest statement

The authors have no conflicts of interest relevant to this article to disclose. Dr. Fox receives research support from Novo Nordisk for an obesity pharmaceutical study. Dr. Kelly serves as a consultant for Novo Nordisk, Orexigen and Vivus Pharmaceuticals; he does not accept personal or professional income for these activities. Dr. Kelly also receives research support from AstraZeneca Pharmaceuticals in the form of drug/placebo. The other authors have no financial relationships relevant to this article to disclose.
Acknowledgements

Author Contributions

CF, JR, ASK, SK and AG conceptualized and designed the study, wrote the initial draft and reviewed and revised the manuscript. AMK and KR completed statistical analyses and reviewed and revised the manuscript. All authors had final approval of the submitted and published versions.

Funding

This work was supported in part by the National Center for Advancing Translational Sciences (award number UL1TR000114).

27 Pediatric Obesity and Weight Evaluation Registry site leads/co-leads and their institutions

1 Abraham-Pratt I. and Fals A. – Florida Hospital for Children (Orlando, FL)
2 Armstrong S. – Duke Children’s Hospital and Health Center (Durham, NC)
3 Binns H. and Ariza A. – Ann & Robert H. Lurie Children’s Hospital of Chicago (Chicago, IL)
4 Borzutzky C. and Fink C. – Children’s Hospital of Los Angeles (Los Angeles, CA)
5 Christison A. – University of Illinois College of Medicine (Peoria, IL)
6 Cuda S. – Children’s Hospital of San Antonio (San Antonio, TX)
7 de la Torre A. – Cook Children’s Medical Center (Fort Worth, TX)
8 Dedekian M. – Barbara Bush Children’s Hospital at Maine Medical Center (Portland, ME)
9 Fox C. and Kelly A. – University of Minnesota Masonic Children’s Hospital (Minneapolis, MN)
10 Gaddis M. and Mitchie J. – St. Luke’s Children’s Hospital (Boise, ID)
11 Grow M. and Liu L. – Seattle Children’s Hospital (Seattle, WA)
12 Herring W. – University of Mississippi Medical Center (Jackson, MS)
13 Joseph M. – UF Health Pediatric Weight Management Center at Wolfson Children’s Hospital (Jacksonville, FL)
14 Kim R. and Gupta O. – Children’s Medical Center/UT Southwestern Medical Center (Dallas, TX)
15 Kirk S. – Cincinnati Children’s Hospital Medical Center (Cincinnati, OH)
16 Kumar S. and Heyman M. – Mayo Clinic (Rochester, MN)
17 Negrete S. and Dalen J. – University of New Mexico Children’s Hospital (Albuquerque, NM)
18 Oden J., Hendrix S. and Ward W. – Arkansas Children’s Hospital (Little Rock, AR)
19 O’Hara V. – Eastern Maine Medical Center (Bangor, ME)
20 Strattbucker W. and Tucker J. – Helen DeVos Children’s Hospital/University of Michigan (Grand Rapids, MI)
21 Sweeney B. – Children’s Mercy Kansas City (Kansas City, MO)
22 Tester J. – Children’s Hospital Oakland (Oakland, CA)
23 Trapp C. and Santos M. – Connecticut Children’s Medical Center (Hartford, CT)
24 Walsh S. – Children’s Hospital of Atlanta (Atlanta, GA)
25 Weedn A. – University of Oklahoma Health Sciences Center (Oklahoma City, OK)
26 Williams R. – Penn State Children’s Hospital (Hershey, PA)
27 Wittcopp C. – Baystate Children’s Hospital (Springfield, MA)

In addition, database programmer, Jennifer Andringa, BA; data specialist, Carolyn Powers, BS, RD, CCDM; SAS programmer, Yahong Liu, MS; manager, Rachel Akers, MPH, CCDM; and Director, Eileen King, PhD, with the POWER Data Coordinating Center in the Division of Biostatistics and Epidemiology, CCHMC, have made important contributions to the management of the POWER data.

References

1. Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120: S164–S192.
2. Kelly AS, Fox CK, Rudser KD, Gross AC, Ryder JR. Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations. Int J Obes (2005). 2016; 40: 1043–1050.
3. Skinner AC, Skelton JA. Prevalence and trends in obesity and severe obesity among children in the United States, 1999-2012. JAMA Pediatr 2014; 168: 561–566.
4. Hebebrand J, Herpertz-Dahlmann B. Psychological and psychiatric aspects of pediatric obesity. Child Adolesc Psychiatr Clin N Am 2009; 18: 49–65.
5. Zeller MH, Modi AC, Noll JG, Long JD, Inge TH. Psychosocial functioning improves following adolescent bariatric surgery. Obesity (Silver Spring) 2009; 17: 985–990.
6. Cortese S, Angriman M, Maffeis C, et al. Attention-deficit/hyperactivity disorder (ADHD) and obesity: a systematic review of the literature. Crit Rev Food Sci Nutr 2008; 48: 524–537.
7. Kirk S, Armstrong S, King E, et al. Establishment of the Pediatric Obesity Weight Evaluation Registry: a national research collaborative for identifying the optimal assessment and treatment of pediatric obesity. *Child Obes* 2017; **13**: 9–17.

8. Johnson CL, Paulose-Ram R, Ogden CL, et al. National health and nutrition examination survey: analytic guidelines, 1999-2010. *Vital Health Stat* **2** 2013: 1–24.

9. Kelly AS, Barlow SE, Rao G, et al. Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific Statement from the American Heart Association. *Circulation* 2013; **128**: 1689–1712.

10. Inge TH, Jenkins TM, Zeller M, et al. Baseline BMI is a strong predictor of nadir BMI after adolescent gastric bypass. *J Pediatr* 2010; **156**: 103–108.e101.

11. Daniels SR, Benuck I, Christakis DA, et al. In: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents Full Report, 2012.

12. Schwimmer JB, Dunn W, Norman GJ, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. *Gastroenterology* 2010; **138**: 1357–1364. e1364.e1351–e1352.

13. Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. *Diabetes Care* 2010; **33**: 2225–2231.

14. Flynn J. The changing face of pediatric hypertension in the era of the childhood obesity epidemic. *Pediatr Nephrol* 2013; **28**: 1059–1066.

15. Freedman DS, Goodman A, Contreras OA, DasMahapatra P, Srinivasan SR, Berenson GS. Secular trends in BMI and blood pressure among children and adolescents: the Bogalusa Heart Study. *Pediatrics* 2012; **130**: e159–e166.

16. Ryder JR, O’Connell M, Bosch TA, et al. Impaired cardiac autonomic nervous system function is associated with pediatric hypertension independent of adiposity. *Pediatr Res* 2016; **79**: 49–54.

17. Bright Futures Guidelines for Health Supervision of Infants, Children and Adolescents, 3rd edn. Elk Grove Village, IL: American Academy of Pediatrics, 2008.

18. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. *Diabetes* 2001; **50**: 2444–2450.

19. Collaboration NRF. Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants. *Lancet Diabetes Endocrinol* 2015; **3**: 624–637.

20. Molleston JP, Schwimmer JB, Yates KP, et al. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. *J Pediatr* 2014; **164**: 707–713.e703.

21. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics* 2006; **118**: 1388–1393.

22. Xanthakos SA, Jenkins TM, Kleiner DE, et al. Cardiovascular risk in 26,008 European overweight children as established by a multicenter database. *Obesity (Silver Spring)* 2008; **16**: 1672–1679.

23. Goldstein BI, Carnethon MR, Matthews KA, et al. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American heart association. *Circulation* 2015; **132**: 965–986.

24. Li L, Perez A, Wu LT, Ranjit N, Brown HS, Kelder SH. Cardiometabolic risk factors among severely obese children and adolescents in the United States, 1999-2012. *Child Obes* 2016; **12**: 12–19.